This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hua, X. H. Articles by Leoni, L. M. Search for Related Content PubMed PubMed Citation Articles by Hua, X. H. Articles by Leoni, L. M.

Biochemical Genetic Analysis of Indanocine Resistance in Human Leukemia¹

Department of Medicine and The Sam and Rose Stein Institute for Research on Aging, University of California, San Diego, La Jolla, California 92093-0663 [X. H. H., D. G., R. T., H. S., T. J. K., D. A. C., L. M. L.], and Target Structure-Based Drug Discovery Group, Information Technology Branch, National Cancer Institute, NIH, Frederick, Maryland 21702 [R. G.]

Indanocine is a potent tubulin-binding drug that is cytotoxic to multidrug-resistant cancer cell lines. We demonstrated that indanocine specifically induces apoptosis in malignant B cells from patients with chronic lymphocytic leukemia. To address the exact biochemical basis for indanocine toxicity, an indanocine-resistant clone was selected from mutagenized CEM human lymphoblastoid cells. The resistant cells displayed a stable indanocine-resistant phenotype for at least 9 months in drug-free culture. The cloned cells are cross-resistant to colchicine and vinblastine, but not to paclitaxel, and do not have increased expression of the multidrug-resistant p170 glycoprotein. In both parental cells and cell extracts, indanocine treatment caused tubulin depolymerization. In contrast, the tubulin in the resistant clone did not depolymerize under identical conditions. Both extract mixing and cell fusion experiments suggested that a stable structural change in microtubules, rather than a soluble factor, was responsible for indanocine resistance. Sequence analysis of parental and resistant cells revealed a single point mutation in the M40 isotype of ß-tubulin at nucleotide 1050 (GT, Lys³⁵⁰Asn) in the indanocine-resistant clone, in a region close to the putative colchicine binding site.

This article has been cited by other articles:

				T. Y.E. Liaw, N. K. Salam, M. J. McKay, A. M. Cunningham, D. E. Hibbs, and M. Kavallaris Class I {beta}-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions Mol. Cancer Ther., October 1, 2008; 7(10): 3150 - 3159. [Abstract] [Full Text] [PDF]

				Y. Gokmen-Polar, D. Escuin, C. D. Walls, S. E. Soule, Y. Wang, K. L. Sanders, T. M. LaVallee, M. Wang, B. D. Guenther, P. Giannakakou, et al. {beta}-Tubulin Mutations Are Associated with Resistance to 2-Methoxyestradiol in MDA-MB-435 Cancer Cells Cancer Res., October 15, 2005; 65(20): 9406 - 9414. [Abstract] [Full Text] [PDF]

				R. E. Ferguson, C. Taylor, A. Stanley, E. Butler, A. Joyce, P. Harnden, P. M. Patel, P. J. Selby, and R. E. Banks Resistance to the Tubulin-Binding Agents in Renal Cell Carcinoma: No Mutations in the Class I {beta}-Tubulin Gene but Changes in Tubulin Isotype Protein Expression Clin. Cancer Res., May 1, 2005; 11(9): 3439 - 3445. [Abstract] [Full Text] [PDF]

				M. Hari, Y. Wang, S. Veeraraghavan, and F. Cabral Mutations in {alpha}- and {beta}-Tubulin That Stabilize Microtubules and Confer Resistance to Colcemid and Vinblastine Mol. Cancer Ther., July 1, 2002; 2(7): 597 - 605. [Abstract] [Full Text] [PDF]

				S. B. Barlow, M. L. Gonzalez-Garay, and F. Cabral Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis J. Cell Sci., January 9, 2002; 115(17): 3469 - 3478. [Abstract] [Full Text] [PDF]

				F. J. Kaye Publishing Negative Data: {beta}-Tubulin Mutations in Lung Cancer J Natl Cancer Inst, December 19, 2001; 93(24): 1832 - 1833. [Full Text] [PDF]